Jeff Sheckter

Triple Five Group Ltd. develops commercial real estate properties. It develops and manages world-scale ventures such as shopping centers, tourism projects, office buildings, urban entertainment destinations, recreation and amusement parks, hospitality projects, and residential developments. The company was founded by Jacob Ghermezian in 1965 and is headquartered in Edmonton, Canada.

Triple Five Group Ltd. develops commercial real estate properties. It develops and manages world-scale ventures such as shopping centers, tourism projects, office buildings, urban entertainment destinations, recreation and amusement parks, hospitality projects, and residential developments. The company was founded by Jacob Ghermezian in 1965 and is headquartered in Edmonton, Canada.

Triple Five Group Ltd. develops commercial real estate properties. It develops and manages world-scale ventures such as shopping centers, tourism projects, office buildings, urban entertainment destinations, recreation and amusement parks, hospitality projects, and residential developments. The company was founded by Jacob Ghermezian in 1965 and is headquartered in Edmonton, Canada.

Triple Five Group Ltd. develops commercial real estate properties. It develops and manages world-scale ventures such as shopping centers, tourism projects, office buildings, urban entertainment destinations, recreation and amusement parks, hospitality projects, and residential developments. The company was founded by Jacob Ghermezian in 1965 and is headquartered in Edmonton, Canada.

Metabolomic Technologies, Inc. is a Canadian company that specializes in developing in vitro diagnostics using metabolomics. Metabolomic Technologies was founded by Haili Wang and Richard Fedorak and is based in Edmonton, CA. The company's lead product, PolypDX™, is a urine-based screening test for colorectal cancer. The company utilizes a unique metabolomics platform to identify distinct metabolic fingerprints and develop accurate diagnostic tests.

Metabolomic Technologies, Inc. is a Canadian company that specializes in developing in vitro diagnostics using metabolomics. Metabolomic Technologies was founded by Haili Wang and Richard Fedorak and is based in Edmonton, CA. The company's lead product, PolypDX™, is a urine-based screening test for colorectal cancer. The company utilizes a unique metabolomics platform to identify distinct metabolic fingerprints and develop accurate diagnostic tests.

Metabolomic Technologies, Inc. is a Canadian company that specializes in developing in vitro diagnostics using metabolomics. Metabolomic Technologies was founded by Haili Wang and Richard Fedorak and is based in Edmonton, CA. The company's lead product, PolypDX™, is a urine-based screening test for colorectal cancer. The company utilizes a unique metabolomics platform to identify distinct metabolic fingerprints and develop accurate diagnostic tests.

Metabolomic Technologies, Inc. is a Canadian company that specializes in developing in vitro diagnostics using metabolomics. Metabolomic Technologies was founded by Haili Wang and Richard Fedorak and is based in Edmonton, CA. The company's lead product, PolypDX™, is a urine-based screening test for colorectal cancer. The company utilizes a unique metabolomics platform to identify distinct metabolic fingerprints and develop accurate diagnostic tests.